Home 2022
Archives
Evaluating a novel treatment for opioid use disorder based on dual-brain psychology and photobiomodulation
Dr. Fredric Schiffer, founder and CEO of MindLight, LLC, looks at treatments for opioid use disorder based on Dual-Brain Psychology and photobiomodulation. Dr. Schiffer is also a part-time assistant professor in psychiatry at Harvard Medical School.
Alzheimer’s drug slows memory decline in phase 3 trial
Henry Scowcroft from Alzheimer’s Research UK, argues that an Alzheimer’s drug, lecanemab, can slow memory decline in a phase 3 trial.
Tuberculosis drug regimens and their efficacies
Andrew Nunn, Professor of Epidemiology in the Medical Research Council Clinical Trials Unit at UCL, analyses tuberculosis drug development.